| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Smith Sandford D serves as a Director at PALI and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 0 buys and 35 sells. Those positions are worth an estimated $1.9M at current prices.
Historically, Smith Sandford D's trades have earned a below-average insider score of 48/100 across 9 rated trades. Over a 12-month horizon, 22.2% of those trades were profitable, with an average 12-month return of -26.3%.
The biggest single holding is CYTK (~$1.4M) as Director. The recent filings there lean toward selling, a net 209,755 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 15, 2020 | CYTK Cytokinetics Inc | Director | Sale+OE | 6,667 | $29.00 | $193,343.00 | -100% | |
| Jul 10, 2020 | CYTK Cytokinetics Inc | Director | Sale+OE | 6,667 | $28.00 | $186,676.00 | -100% | |
| Jul 8, 2020 | CYTK Cytokinetics Inc | Director | Sale+OE | 13,176 | $26.51 | $349,242.00 | -100% | |
| Jun 22, 2020 | CYTK Cytokinetics Inc | Director | Sale+OE | 10,000 | $24.50 | $245,000.00 | -100% | |
| Jun 17, 2020 | CYTK Cytokinetics Inc | Director | Sale+OE | 6,907 | $23.00 | $158,861.00 | -100% | |
| Jun 15, 2020 | CYTK Cytokinetics Inc | Director | Sale+OE | 6,666 | $22.00 | $146,652.00 | -100% | |
| Jun 12, 2020 | CYTK Cytokinetics Inc | Director | Sale+OE | 15,045 | $20.86 | $313,907.30 | -100% |